Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma

Lancet Oncol. 2016 Jan;17(1):e4-5. doi: 10.1016/S1470-2045(15)00543-4. Epub 2015 Dec 23.

Authors

Robert J Motzer¹, Thomas E Hutson², Min Ren³, Corina Dutcus³, James Larkin⁴

Affiliations

¹ Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA. Electronic address: motzerr@mskcc.org.
² Texas Oncology, Dallas, TX, USA.
³ Eisai Inc, Woodcliff Lake, NJ, USA.
⁴ Royal Marsden Hospital NHS Foundation Trust, London, UK.

PMID: 26758760
DOI: 10.1016/S1470-2045(15)00543-4

No abstract available

Publication types

Clinical Trial, Phase II
Comparative Study
Letter
Randomized Controlled Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / diagnostic imaging*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / secondary
Disease-Free Survival
Everolimus / administration & dosage
Female
Humans
Kidney Neoplasms / diagnostic imaging*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / pathology
Magnetic Resonance Imaging
Male
Phenylurea Compounds / administration & dosage
Quinolines / administration & dosage
Response Evaluation Criteria in Solid Tumors
Retrospective Studies
Single-Blind Method
Tomography, X-Ray Computed

Substances

Phenylurea Compounds
Quinolines
Everolimus
lenvatinib